keyword
MENU ▼
Read by QxMD icon Read
search

Radioembolization

keyword
https://www.readbyqxmd.com/read/28534347/recent-perspectives-of-management-of-breast-cancer-metastasis-an-update
#1
Qingzhong Tian, Yun Wang, Hao Guo, Guangwei Xie, Jin Li, Minkang Zhang, Qianjin Zhang, Qingliang Meng
Breast cancer is the leading cause of cancer related deaths in women and one of the most common cancers globally. The major obstacle in the management of breast cancer, especially at advanced stages, is metastasis. Metastasis in the advanced stages of breast cancer could decrease survival to approximately 5 years. The reasons could include lack of targeted receptors or chemotherapeutic agents for the management of advanced-stage breast cancer metastasis. The new emerging avenues for the management of this deadly pathological state include local manipulations like radiofrequency ablation (RFA), microwave thermotherapy, cryosurgery (cryotherapy), chemoembolization, radioembolization, breast surgery, or metastasectomy...
March 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/28534185/erratum-to-yttrium-90-radioembolization-for-unresectable-combined-hepatocellular-cholangiocarcinoma
#2
Lauren S Chan, Daniel Y Sze, George A Poultsides, John D Louie, Mohammed A Abdelrazek Mohammed, David S Wang
No abstract text is available yet for this article.
May 22, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28527884/adjuvant-medications-that-improve-survival-after-locoregional-therapy
#3
F Edward Boas, Etay Ziv, Hooman Yarmohammadi, Karen T Brown, Joseph P Erinjeri, Constantinos T Sofocleous, James J Harding, Stephen B Solomon
PURPOSE: To determine if outpatient medications taken at the time of liver tumor embolization or ablation affect survival. MATERIALS AND METHODS: A retrospective review was done of 2,032 liver tumor embolization, radioembolization, and ablation procedures performed in 1,092 patients from June 2009 to April 2016. Pathology, hepatocellular carcinoma (HCC) stage (American Joint Committee on Cancer), neuroendocrine tumor (NET) grade, initial locoregional therapy, overall survival after initial locoregional therapy, Child-Pugh score, Eastern Cooperative Oncology Group performance status, Charlson Comorbidity Index, and outpatient medications taken at the time of locoregional therapy were analyzed for each patient...
May 17, 2017: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/28509806/advances-in-management-of-hepatocellular-carcinoma
#4
Manon Allaire, Jean-Charles Nault
PURPOSE OF REVIEW: Hepatocellular carcinoma (HCC) is one of the leading causes of death by cancer worldwide due to a dismal prognosis. The aim of this review is to summarize the main advances in the pathophysiology and management of HCC. RECENT FINDINGS: Genomic analysis has recently delineated the key signaling pathways aberrantly deregulated in HCC (telomere maintenance, cell cycle gene, Wnt/β-catenin, epigenetic modifier, oxidative stress etc.). Major advances in the clinical care of patients with HCC are helping to refine the diagnosis algorithm and tumor staging...
May 15, 2017: Current Opinion in Oncology
https://www.readbyqxmd.com/read/28509566/respiratory-motion-during-90-yttrium-pet-contributes-to-underestimation-of-tumor-dose-and-overestimation-of-normal-liver-tissue-dose
#5
Line Ausland, Mona-Elisabeth Revheim, Arne Skretting, Caroline Stokke
Background Yttrium-90 dosimetry after radioembolization is reliant on accurate quantitative imaging of the microsphere deposition. Previous studies have focused on the correction of geometrical resolution effects. Purpose To uncover additional effects of respiratory motion. Material and Methods Mathematical models describing spherical tumors were formed and two blurring effects, limited geometrical resolution and respiratory motion, were simulated. The virtual images were used as basis for dose volume histogram estimations by convolving the radioactivity representations with a dose point kernel...
January 1, 2017: Acta Radiologica
https://www.readbyqxmd.com/read/28500460/prophylactic-temporary-occlusion-of-the-cystic-artery-using-a-fibered-detachable-coil-during-90-y-radioembolization
#6
Jin Woo Choi, Min Young Yoo, Hyo-Cheol Kim, Jin Chul Paeng, Yoon Jun Kim, Jin Wook Chung
PURPOSE: To address the feasibility of prophylactic temporary occlusion of the cystic artery using a detachable coil during (90)Y radioembolization. MATERIALS AND METHODS: From January 2012 to October 2016, nine patients underwent temporary occlusion of the cystic artery during (90)Y radioembolization. Based on the planning hepatic angiography, a detachable coil was deployed into the cystic artery, which arose from a more distal level (e.g., right anterior hepatic artery) than its usual origin, but the proximal 1 cm was left inside the microcatheter...
May 12, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28494530/radioembolization-for-the-treatment-of-hepatocellular-carcinoma
#7
Hyo-Cheol Kim
Transarterial radioembolization (TARE) with yttrium 90 (90Y), an intra-arterial procedure performed by interventional radiologists, has begun being utilized in managing hepatocellular carcinoma (HCC) in Korea. There are two available TARE products: glass and resin microspheres with different physical characteristics. All patients undergoing TARE must be assessed with clinical examination and laboratory tests as well as a thorough angiographic evaluation. TARE is safe and effective in the treatment of unresectable HCC, as it has longer time-to-progression, greater ability to downsize tumors for liver transplantation, less post-embolization syndrome, and shorter hospitalization compared with chemoembolization...
May 10, 2017: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/28490991/other-non-surgical-treatments-for-liver-cancer
#8
Paul Revel-Mouroz, Philippe Otal, Marion Jaffro, Antoine Petermann, Olivier Meyrignac, Pierre Rabinel, Fatima-Zohra Mokrane
Interventional radiology plays a major role in the modern management of liver cancers, in primary hepatic malignancies or metastases and in palliative or curative situations. Radiological treatments are divided in two categories based on their approach: endovascular treatment and direct transcapsular access. Endovascular treatments include mainly three applications: transarterial chemoembolization (TACE), transarterial radioembolization (TARE) and portal vein embolization (PVE). TACE and TARE share an endovascular arterial approach, consisting of a selective catheterization of the hepatic artery or its branches...
March 2017: Reports of Practical Oncology and Radiotherapy
https://www.readbyqxmd.com/read/28482674/management-of-hepatocellular-in-the-united-states
#9
Ali A Mokdad, Caitlin A Hester, Amit G Singal, Adam C Yopp
Hepatocellular carcinoma (HCC) is a major cause of cancer burden globally. In the United States, the incidence of HCC is forecast to continue to rise for the next 15 years. Patients with HCC vary markedly owing to heterogeneous tumor characteristics and concomitant liver dysfunction. In the United States and Europe, HCC is staged and managed according to the Barcelona Clinic Liver Cancer (BCLC) system. For very early and early stage HCC, or BCLC 0/A, liver transplant is the optimal treatment option. Liver resection and radiofrequency or microwave ablation are alternative treatment options...
April 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/28480062/locoregional-and-systemic-therapy-for-hepatocellular-carcinoma
#10
REVIEW
Olumide B Gbolahan, Michael A Schacht, Eric W Beckley, Thomas P LaRoche, Bert H O'Neil, Maximilian Pyko
The management of hepatocellular carcinoma (HCC) remains challenging due to late presentation and the presence of accompanying liver dysfunction. As such, most patients are not eligible for curative resection and liver transplant. Management in this scenario depends on a number of factors including hepatic function, tumor burden, patency of hepatic vasculature and patients' functional status. Based on these, patients can be offered catheter based intra-arterial therapy for intermediate stage disease and in more advanced disease, sorafenib...
April 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28474382/the-role-of-angled-tip-microcatheter-and-microsphere-injection-velocity-in-liver-radioembolization-a-computational-particle-hemodynamics-study
#11
Jorge Aramburu, Raúl Anton, Alejandro Rivas, Juan Carlos Ramos, Bruno Sangro, José Ignacio Bilbao
Liver radioembolization is a promising treatment option for combating liver tumors. It is performed by placing a microcatheter in the hepatic artery and administering radiation-emitting microspheres through the arterial bloodstream so that they get lodged in the tumoral bed. In avoiding nontarget radiation, the standard practice is to conduct a pretreatment, in which the microcatheter location and injection velocity are decided. However, between pretreatment and actual treatment some of the parameters that influence the particle distribution in the liver can vary, resulting in radiation-induced complications...
May 4, 2017: International Journal for Numerical Methods in Biomedical Engineering
https://www.readbyqxmd.com/read/28432387/yttrium-90-radioembolization-for-unresectable-combined-hepatocellular-cholangiocarcinoma
#12
Lauren S Chan, Daniel Y Sze, George A Poultsides, John D Louie, Mohammed A Abdelrazek Mohammed, David S Wang
PURPOSE: Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare mixed cell type primary liver cancer with limited data to guide management. Transarterial radioembolization with yttrium-90 microspheres (RE) is an emerging treatment option for both hepatocellular carcinoma and intrahepatic cholangiocarcinoma. This study explored the safety and efficacy of RE for unresectable cHCC-CC. METHODS: Patients with histopathologically confirmed cHCC-CC treated with RE were retrospectively evaluated...
April 21, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28421483/update-on-embolization-therapies-for-hepatocellular-carcinoma
#13
REVIEW
Sirish Kishore, Tamir Friedman, David C Madoff
PURPOSE OF REVIEW: The purpose of the review is to summarize the latest applications for embolotherapy in the management of patients with HCC according to BCLC stage. RECENT FINDINGS: While traditionally reserved for patients with unresectable HCC and stage B disease, there is an important role for embolization therapies in earlier stage patients as an adjunct to ablation, bridging, or downstaging therapy, as a means to improve safety of resection, and potentially as an arterial ablative option in the case of radioembolization...
June 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28418940/assessment-of-the-albumin-bilirubin-albi-grade-as-a-prognostic-indicator-for-hepatocellular-carcinoma-patients-treated-with-radioembolization
#14
Bin Gui, Ashley A Weiner, John Nosher, Shou-En Lu, Gretchen M Foltz, Omar Hasan, Seung K Kim, Vyacheslav Gendel, Naganathan B Mani, Darren R Carpizo, Nael E Saad, Timothy J Kennedy, Darryl A Zuckerman, Jeffrey R Olsen, Parag J Parikh, Salma K Jabbour
OBJECTIVE: As the utility of Child-Pugh (C-P) class is limited by the subjectivity of ascites and encephalopathy, we evaluated a previously established objective method, the albumin-bilirubin (ALBI) grade, as a prognosticator for yttrium-90 radioembolization (RE) treatment for patients with hepatocellular carcinoma (HCC). MATERIALS AND METHODS: A total of 117 patients who received RE for HCC from 2 academic centers were reviewed and stratified by ALBI grade, C-P class, and Barcelona Clinic Liver Cancer stage...
April 17, 2017: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28415671/predictors-and-prognosticators-for-survival-with-yttrium-90-radioembolization-therapy-for-unresectable-colorectal-cancer-liver-metastasis
#15
REVIEW
Meaghan S Dendy, Johannes M Ludwig, Hyun S Kim
This critical review aims to explore predictive and prognostic biomarkers of Yttrium-90 (Y90) radioembolization therapy of colorectal liver metastases. A brief overview of established predictive and prognostic molecular and genetic biomarkers in colorectal cancer therapies will be discussed. A review of the literature on imaging modalities, genetic, metabolic and other molecular markers and the subsequent outcomes in post-Y90 treatment will be presented. How these biomarkers and future biomarker research can inform locoregional treatment decisions in the clinical setting of metastatic colorectal cancer lesions of the liver will be explored...
March 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28408731/long-term-outcome-after-liver-transplantation-for-hepatocellular-carcinoma-following-yttrium-90-radioembolization-bridging-treatment
#16
Sonia Radunz, Jürgen Treckmann, Hideo A Baba, Jan Best, Stefan Müller, Jens M Theysohn, Andreas Paul, Tamás Benkö
BACKGROUND Bridging treatments are employed in liver transplant waitlist patients with hepatocellular carcinoma (HCC) because of the risk of tumor progression during the waiting time. Radioembolization is mostly employed in the control of large or multifocal HCCs when other locoregional treatment modalities cannot be applied because of the number or size of lesions. The purpose of this study was to evaluate our experience with the use of radioembolization as a bridge to transplantation and its effect on tumor recurrence and survival after liver transplantation...
April 14, 2017: Annals of Transplantation: Quarterly of the Polish Transplantation Society
https://www.readbyqxmd.com/read/28405728/clinical-feasibility-of-90-y-digital-pet-ct-for-imaging-microsphere-biodistribution-following-radioembolization
#17
Chadwick L Wright, Katherine Binzel, Jun Zhang, Evan J Wuthrick, Michael V Knopp
PURPOSE: The purpose of this study was to evaluate the clinical feasibility of next generation solid-state digital photon counting PET/CT (dPET/CT) technology and imaging findings in patients following (90)Y microsphere radioembolization in comparison with standard of care (SOC) bremsstrahlung SPECT/CT (bSPECT/CT). METHODS: Five patients underwent SOC (90)Y bremsstrahlung imaging immediately following routine radioembolization with 3.5 ± 1.7 GBq of (90)Y-labeled glass microspheres...
April 12, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28365172/segmental-yttrium-90-radioembolization-versus-segmental-chemoembolization-for-localized-hepatocellular-carcinoma-results-of-a-single-center-retrospective-propensity-score-matched-study
#18
Siddharth A Padia, Guy E Johnson, Kathryn J Horton, Christopher R Ingraham, Matthew J Kogut, Sharon Kwan, Sandeep Vaidya, Wayne L Monsky, James O Park, Renuka Bhattacharya, Daniel S Hippe, William P Harris
PURPOSE: To compare segmental radioembolization with segmental chemoembolization for localized, unresectable hepatocellular carcinoma (HCC) not amenable to ablation. MATERIALS AND METHODS: In a single-center, retrospective study (2010-2015), 101 patients with 132 tumors underwent segmental radioembolization, and 77 patients with 103 tumors underwent segmental doxorubicin-based drug-eluting embolic or conventional chemoembolization. Patients receiving chemoembolization had worse performance status (Eastern Cooperative Oncology Group 0, 76% vs 56%; P = ...
March 30, 2017: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/28357572/safety-and-efficacy-of-y-90-radioembolization-after-prior-major-hepatic-resection
#19
Markus Zimmermann, Maximilian Schulze-Hagen, Martin Liebl, Federico Pedersoli, Fabian Goerg, Tom Florian Ulmer, Alexander Heinzel, Peter Isfort, Christiane Kuhl, Philipp Bruners
PURPOSE: To evaluate the safety and efficacy of yttrium-90 radioembolization (RE) following left or right hepatic lobectomy. MATERIALS AND METHODS: Between 2011 and 2016, 15 patients underwent RE with Y90-resin microspheres following right (8/15) or left (7/15) hepatic lobectomy. In eight patients, the whole liver remnant was treated during a single session, whereas the remaining seven patients received up to 3 selective RE at 1- to 2-month intervals. The administered patient activity was calculated based on the body surface area (BSA) method in all cases...
March 29, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28351831/protocol-for-combined-analysis-of-foxfire-sirflox-and-foxfire-global-randomized-phase-iii-trials-of-chemotherapy-selective-internal-radiation-therapy-as-first-line-treatment-for-patients-with-metastatic-colorectal-cancer
#20
Pradeep S Virdee, Joanna Moschandreas, Val Gebski, Sharon B Love, E Anne Francis, Harpreet S Wasan, Guy van Hazel, Peter Gibbs, Ricky A Sharma
BACKGROUND: In colorectal cancer (CRC), unresectable liver metastases are associated with a poor prognosis. The FOXFIRE (an open-label randomized phase III trial of 5-fluorouracil, oxaliplatin, and folinic acid +/- interventional radioembolization as first-line treatment for patients with unresectable liver-only or liver-predominant metastatic colorectal cancer), SIRFLOX (randomized comparative study of FOLFOX6m plus SIR-Spheres microspheres versus FOLFOX6m alone as first-line treatment in patients with nonresectable liver metastases from primary colorectal carcinoma), and FOXFIRE-Global (assessment of overall survival of FOLFOX6m plus SIR-Spheres microspheres versus FOLFOX6m alone as first-line treatment in patients with nonresectable liver metastases from primary colorectal carcinoma in a randomized clinical study) clinical trials were designed to evaluate the efficacy and safety of combining first-line chemotherapy with selective internal radiation therapy (SIRT) using yttrium-90 resin microspheres, also called transarterial radioembolization...
March 28, 2017: JMIR Research Protocols
keyword
keyword
13605
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"